BeOne Medicines Ltd. (SHA:688235)
245.54
-3.92 (-1.57%)
Aug 6, 2025, 3:00 PM CST
Six Flags Entertainment Revenue
BeOne Medicines had revenue of $1.32B USD in the quarter ending June 30, 2025, with 41.56% growth. This brings the company's revenue in the last twelve months to $4.56B, up 47.33% year-over-year. In the year 2024, BeOne Medicines had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.56B
Revenue Growth
+47.33%
P/S Ratio
7.78
Revenue / Employee
$414.73K
Employees
11,000
Market Cap
254.41B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 41.48B |
Sichuan Biokin Pharmaceutical | 5.82B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |
BeOne Medicines News
- 6 weeks ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 2 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn
- 2 months ago - Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
- 2 months ago - BeiGene gets EU backing for neck and head cancer treatment - Seeking Alpha
- 2 months ago - Market Shrugs Off This Drugmaker's Turnaround - Benzinga
- 3 months ago - Earnings Preview: BeiGene - Benzinga
- 3 months ago - Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + - Seeking Alpha
- 3 months ago - BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit - Seeking Alpha